1.

A belgian survey on the diagnosis of asthma– COPD overlap syndrome

2.

A belgian survey on the diagnosis of asthma– COPD overlap syndrome

3.

A belgian survey on the diagnosis of asthma– COPD overlap syndrome

1.

A Belgian survey on the diagnosis of asthma–COPD overlap syndrome

1.

A Belgian survey on the diagnosis of asthma-COPD overlap syndrome.

2.

A Belgian survey on the diagnosis of asthma-COPD overlap syndrome.

3.

A Belgian survey on the diagnosis of asthma-COPD overlap syndrome.

4.

A Belgian survey on the diagnosis of asthma-COPD overlap syndrome.

5.

A Belgian survey on the diagnosis of asthma-COPD overlap syndrome.

1.

Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry.

2.

Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry.

3.

Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry.

1.

A Belgian survey on the diagnosis of asthma–COPD overlap syndrome

2.

A Belgian survey on the diagnosis of asthma–COPD overlap syndrome

3.

A Belgian survey on the diagnosis of asthma–COPD overlap syndrome

1.

A Belgian survey on the diagnosis of asthma-COPD overlap syndrome

1.

COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry.

2.

COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry.

3.

COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry.

4.

COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry.

5.

COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry.

1.

COVID-19 and biologics in severe asthma : data from the Belgian Severe Asthma Registry

1.

Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature

1.

Anti-IL5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian Severe Asthma Registry.

2.

Anti-IL5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian Severe Asthma Registry.

3.

Anti-IL5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian Severe Asthma Registry.